Key Points
- Director Martin Marino bought more Microbix Biosystems shares, acquiring 69,000 shares on May 26 at C$0.26 each for C$17,940. After the purchase, he owned 1,860,667 shares, a 3.85% increase in his stake.
- Marino continued buying after that transaction, adding 24,500 shares on May 27 and 115,000 shares on May 28, signaling repeated insider buying over several days.
- Microbix Biosystems’ stock and fundamentals remain under pressure, with shares down 1.8% and the company reporting a recent quarterly loss of C($0.01) per share on revenue of C$3.38 million. The company also posted negative net margin and return on equity, though analysts still expect a small profit this fiscal year.
Microbix Biosystems Inc. (TSE:MBX - Get Free Report) Director Martin Marino acquired 69,000 shares of the business's stock in a transaction on Tuesday, May 26th. The stock was bought at an average cost of C$0.26 per share, for a total transaction of C$17,940.00. Following the completion of the transaction, the director directly owned 1,860,667 shares of the company's stock, valued at C$483,773.42. This trade represents a 3.85% increase in their ownership of the stock.
Martin Marino also recently made the following trade(s):
- On Thursday, May 28th, Martin Marino acquired 115,000 shares of Microbix Biosystems stock. The stock was bought at an average cost of C$0.28 per share, for a total transaction of C$32,200.00.
- On Wednesday, May 27th, Martin Marino acquired 24,500 shares of Microbix Biosystems stock. The stock was bought at an average cost of C$0.26 per share, for a total transaction of C$6,370.00.
Microbix Biosystems Trading Down 1.8%
TSE:MBX opened at C$0.28 on Friday. The business's 50-day moving average is C$0.24 and its two-hundred day moving average is C$0.24. The company has a debt-to-equity ratio of 27.03, a current ratio of 5.35 and a quick ratio of 5.57. Microbix Biosystems Inc. has a 12 month low of C$0.21 and a 12 month high of C$0.34. The firm has a market capitalization of C$37.81 million, a PE ratio of -6.71 and a beta of 0.48.
Microbix Biosystems (TSE:MBX - Get Free Report) last released its quarterly earnings data on Thursday, May 14th. The company reported C($0.01) EPS for the quarter. Microbix Biosystems had a negative net margin of 38.62% and a negative return on equity of 21.02%. The company had revenue of C$3.38 million during the quarter. Research analysts predict that Microbix Biosystems Inc. will post 0.02 earnings per share for the current fiscal year.
About Microbix Biosystems
(
Get Free Report)
Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
